ClinicalTrials.gg
CompletedNCT00984386Updated Sep 25, 2009

Investigation of the Efficacy of Zesteem in Accelerating Early Wound Healing

A Phase 2 interventional study of Zesteem and Zesteem in Cicatrix and Wound-healing, sponsored by Renovo. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-09-25.

Sponsored by Renovo · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Cicatrix by Renovo — none open to participants now, none under way, none of them phase 3. Cicatrix · Renovo.

Enrollment
16th of 23
44 · median 63
Started
2005
with 1 other
Phase 2
12 of 23
none open now
Registered
17th of 23
by date

Among the 23 studies in Cicatrix by Renovo, this one is the 16th largest by enrollment, is one of 2 that started in 2005, is one of 12 in phase 2, and was the 17th registered.

Cicatrix

613 studies on the registry are indexed under Cicatrix; 115 are open to participants now.

Browse Cicatrix studies →

Open to participants now

None of the 23 studies in Cicatrix by Renovo is open now. The open studies under Cicatrix, anywhere →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Cicatrix by Renovo as a file.
02

Study summary

The purpose of this study is to investigate early wound healing of one application of four different doses of intradermal Zesteem (17β-Estradiol) in male subjects and female subjects two years post-menopausal.

Read the detailed description

Each subject received a total of six, 3mm punch biopsy wounds; three wounds to the upper inner aspect of each arm. Each punch biopsy site was randomly allocated to receive one of six treatments: Zesteem (0.02μg, 0.1μg, 0.2μg and 0.4μg/100μl), Placebo (vehicle), and Standard Care (moist wound healing dressings) only.

Zesteem and Placebo were administered to marked, anaesthetised sites, by intradermal injection 10 to 30 minutes before wounding. Sites randomised to receive Standard Care only received no additional treatment before wounding. After wounding, all sites received moist wound healing dressings (Standard Care).

Three days after wounding, all biopsy sites were anaesthetised and the wounds excised using a 5mm punch biopsy, for histological analysis. The Investigator closed all excision sites using sutures and Steri-strips to achieve a cosmetically acceptable result. Subjects attended a post-trial follow-up visit (13-18 days after dosing) where their sutures were removed and final safety assessments were performed.

03

Conditions studied

  • Cicatrix
  • Wound-healing

Browse trials for

Keywords

  • Cicatrix
  • Scar
  • Wound-healing
  • Zesteem
  • 17β-Estradiol
  • RN1002
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects aged 18-85 years, and female subjects who are at least two years (quantified by a serum test result of estradiol \<90 pmol/L and FSH > 31 IU/L) who have given written
  • Subjects with a within the permitted range for their height using Quetelet's index-weight (kg)/height² (m). The permitted index is 15-55 kg/m2
  • Subjects with, in the opinion of the investigator, clinically acceptable results for laboratory safety tests performed within 28 days of the first trial dose administration

Exclusion criteria

Exclusion Criteria:

  • Subjects who on direct questioning and physical examination have history or evidence of hypertrophic or keloid scarring
  • Subjects with tattoos or previous scars within 3cm of the area to be biopsied
  • Afro-Caribbean subjects are excluded because of the increased susceptibility to hypertrophic and keloid scarring
  • Subjects who have had surgery in the area to be biopsied within one year of the first dosing day
  • Subjects with a history of a bleeding disorder
  • Subjects with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial
  • Subjects with any medical condition or history that would impair wound healing including: significant rheumatoid arthritis, chronic renal impairment significant for their age, significant hepatic impairment (LFTs >3 times ), congestive heart failure, current active or history of malignancy in the last 5 years, or chemotherapy within the last 12 months, a history of radiotherapy or diabetes mellitus
  • Subjects with a history of to any of the drugs or dressings used in this trial
  • Subjects who are taking, or have taken any product or participated in a clinical trial in the three months prior to first trial dose administration
  • Subjects who are taking regular, continuous, oral therapy
  • Subjects undergoing investigations or changes in management for an existing medical condition
  • Subjects with a history of drug abuse
  • Subjects with a positive drugs of abuse test for cocaine, amphetamines, methamphetamines, opiates or benzodiazepines during the screening period
  • Subjects who, in the opinion of the investigator, are unlikely to complete the trial for whatever reason
  • Female subjects who are currently taking any form of hormone replacement therapy or medication
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Intradermal Zesteem

    Drug: Zesteem

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy

    Also known as: 17β-Estradiol, RN1002

  • Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy

    Also known as: 17β-Estradiol, RN1002

  • Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy

    Also known as: 17β-Estradiol, RN1002

  • Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy

    Also known as: 17β-Estradiol, RN1002

  • DrugPlacebo

    Intradermal placebo, 100μl administered once before punch biopsy

06

What researchers measure

Primary outcomes

  1. To assess acceleration of early wound healing in male and postmenopausal female subjects following administration of intradermal Zesteem. The primary trial endpoint will be the distance travelled by the epithelium over the biopsy site.

    Time frame: Day 3

Secondary outcomes

  1. To assess safety and tolerability of intradermal Zesteem in male and post-menopausal female subjects.

    Time frame: 13-18 Days

07

Study locations

1 site
  • Renovo Clinical Trials Unit
    Manchester, M13 9XX, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2009
First posted
Sep 25, 2009
Start
Mar 2005
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Last update
Sep 25, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00984386
Lead sponsor
Renovo
First posted
Sep 25, 2009
Start date
Mar 2005
Primary completion
Apr 2005
Completion
Apr 2005
Last update
Sep 25, 2009

Study contacts

Jonathan Duncan
principal investigator · Renovo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion